FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus
- Autores
- Bidart, Juan Esteban; Mignaqui, Ana Clara; Kornuta, Claudia Alejandra; Lupi, Giuliana; Gammella, Mariela; Soria, Ivana; Galarza, Roxana Ivon; Ferella, Alejandra; Cardillo, Sabrina Beatriz; Langellotti, Cecilia Ana; Quattrocchi, Valeria; Durocher, Yves; Wigdorovitz, Andres; Marcipar, Ivan; Zamorano, Patricia Ines
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Foot and Mouth Disease Virus (FMDV) causes economy losses and is controlled by vaccination in many countries. Vaccine formulations based on empty capsids or Virus-Like Particles (VLPs) have the advantage of avoiding the biological hazard of using infectious FMDV, albeit are poorly immunogenic. Recently, we have described that ISPA a new Immune Stimulating Complex adjuvant, is useful to improve the response against FMD of vaccines that use inactivated virus. Now, the adjuvant effects of ISPA and ISA 206 (water/oil/water) on a VLPs-based FMD vaccine were evaluated. VLPs (strain A/Argentina/2001) were obtained in mammalian cell cultures and their elicitation of an immune response against FMDV with and without ISPA or ISA 206 was evaluated in mice as a first approach. Notably, VLPs-ISPA and VLPs-ISA 206 vaccines induced protection against viral challenge in 100 % of mice, while protection induced by VLPs alone was of 40 %. Total and neutralizing FMDV antibodies were higher in the VLPs-ISPA and VLPs-ISA 206 groups compared to the VLPs group. VLPs-ISPA induced significantly higher (p < 0.001) IgG1, IgG2a, IgG2b and IgG3 titers than the VLPs vaccine. Moreover, in comparison with non-adjuvanted VLPs, VLPs-ISPA and VLPs-ISA 206 elicited an increased virus-specific T response, including higher IFNγ+/CD8 + lymphocyte production in mice. When these vaccines were tested in calves, antibody titers reached an Expected Percentage of Protection (EPP) above 90 % in the case of the VLPs-ISPA and VLPs-ISA 206 vaccines, while, in the VLPs group, EPP reached 25 %. IFNγ levels secreted by mononuclear cells of VLP-ISPA-vaccinated cattle were significantly higher than in the VLPs group. Overall, the results demonstrate that VLPs-ISPA or VLPs-ISA 206 are promising formulations for the development of a novel FMD vaccine.
Instituto de Virología
Fil: Bidart, Juan Esteban. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Bidart, Juan Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina
Fil: Mignaqui, Ana Clara. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Kornuta, Claudia Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Kornuta, Claudia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Lupi, Giuliana. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas; Argentina
Fil: Lupi, Giuliana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gammella, Mariela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Gammella, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Soria, Ivana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Galarza, Roxana Ivon. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Galarza, Roxana Ivon. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Ferella, Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; Argentina
Fil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Langellotti, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Quattrocchi, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; Canadá
Fil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Wigdorovitz, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Marcipar, Ivan Sergio. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Tecnología Inmunológica; Argentina
Fil: Marcipar, Ivan Sergio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Zamorano, Patricia Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Zamorano, Patricia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Zamorano, Patricia Ines. Universidad del Salvador; Argentina - Fuente
- Virus Research 297 : 198339 (Mayo 2021)
- Materia
-
Foot-and-mouth Disease
Aphthovirus
Vaccine Adjuvants
Immunity
Protection
Fiebre Aftosa
Virus Fiebre Aftosa
Coadyuvantes de Vacunas
Inmunidad
Protección - Nivel de accesibilidad
- acceso restringido
- Condiciones de uso
- Repositorio
.jpg)
- Institución
- Instituto Nacional de Tecnología Agropecuaria
- OAI Identificador
- oai:localhost:20.500.12123/10200
Ver los metadatos del registro completo
| id |
INTADig_7b1595a95e359c514e5711432731a131 |
|---|---|
| oai_identifier_str |
oai:localhost:20.500.12123/10200 |
| network_acronym_str |
INTADig |
| repository_id_str |
l |
| network_name_str |
INTA Digital (INTA) |
| spelling |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virusBidart, Juan EstebanMignaqui, Ana ClaraKornuta, Claudia AlejandraLupi, GiulianaGammella, MarielaSoria, IvanaGalarza, Roxana IvonFerella, AlejandraCardillo, Sabrina BeatrizLangellotti, Cecilia AnaQuattrocchi, ValeriaDurocher, YvesWigdorovitz, AndresMarcipar, IvanZamorano, Patricia InesFoot-and-mouth DiseaseAphthovirusVaccine AdjuvantsImmunityProtectionFiebre AftosaVirus Fiebre AftosaCoadyuvantes de VacunasInmunidadProtecciónFoot and Mouth Disease Virus (FMDV) causes economy losses and is controlled by vaccination in many countries. Vaccine formulations based on empty capsids or Virus-Like Particles (VLPs) have the advantage of avoiding the biological hazard of using infectious FMDV, albeit are poorly immunogenic. Recently, we have described that ISPA a new Immune Stimulating Complex adjuvant, is useful to improve the response against FMD of vaccines that use inactivated virus. Now, the adjuvant effects of ISPA and ISA 206 (water/oil/water) on a VLPs-based FMD vaccine were evaluated. VLPs (strain A/Argentina/2001) were obtained in mammalian cell cultures and their elicitation of an immune response against FMDV with and without ISPA or ISA 206 was evaluated in mice as a first approach. Notably, VLPs-ISPA and VLPs-ISA 206 vaccines induced protection against viral challenge in 100 % of mice, while protection induced by VLPs alone was of 40 %. Total and neutralizing FMDV antibodies were higher in the VLPs-ISPA and VLPs-ISA 206 groups compared to the VLPs group. VLPs-ISPA induced significantly higher (p < 0.001) IgG1, IgG2a, IgG2b and IgG3 titers than the VLPs vaccine. Moreover, in comparison with non-adjuvanted VLPs, VLPs-ISPA and VLPs-ISA 206 elicited an increased virus-specific T response, including higher IFNγ+/CD8 + lymphocyte production in mice. When these vaccines were tested in calves, antibody titers reached an Expected Percentage of Protection (EPP) above 90 % in the case of the VLPs-ISPA and VLPs-ISA 206 vaccines, while, in the VLPs group, EPP reached 25 %. IFNγ levels secreted by mononuclear cells of VLP-ISPA-vaccinated cattle were significantly higher than in the VLPs group. Overall, the results demonstrate that VLPs-ISPA or VLPs-ISA 206 are promising formulations for the development of a novel FMD vaccine.Instituto de VirologíaFil: Bidart, Juan Esteban. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Bidart, Juan Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; ArgentinaFil: Mignaqui, Ana Clara. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Kornuta, Claudia Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Kornuta, Claudia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Lupi, Giuliana. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas; ArgentinaFil: Lupi, Giuliana. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gammella, Mariela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Gammella, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Soria, Ivana. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Galarza, Roxana Ivon. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Galarza, Roxana Ivon. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Ferella, Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; ArgentinaFil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Langellotti, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Quattrocchi, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; CanadáFil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Wigdorovitz, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Marcipar, Ivan Sergio. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Tecnología Inmunológica; ArgentinaFil: Marcipar, Ivan Sergio. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Zamorano, Patricia Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Zamorano, Patricia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Zamorano, Patricia Ines. Universidad del Salvador; ArgentinaElsevier2021-09-08T12:05:18Z2021-09-08T12:05:18Z2021-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/10200https://www.sciencedirect.com/science/article/abs/pii/S01681702210004601872-7492https://doi.org/10.1016/j.virusres.2021.198339Virus Research 297 : 198339 (Mayo 2021)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repograntAgreement/INTA/2019-PD-E5-I105-001/2019-PD-E5-I105-001/AR./Patógenos animales: su interacción con el hospedador y el medio ambiente. Impacto en productividad, ecosistemas, sanidad animal y salud pública en el marco “Una Salud”info:eu-repo/semantics/restrictedAccess2025-10-16T09:30:13Zoai:localhost:20.500.12123/10200instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-10-16 09:30:13.612INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse |
| dc.title.none.fl_str_mv |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| spellingShingle |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus Bidart, Juan Esteban Foot-and-mouth Disease Aphthovirus Vaccine Adjuvants Immunity Protection Fiebre Aftosa Virus Fiebre Aftosa Coadyuvantes de Vacunas Inmunidad Protección |
| title_short |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_full |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_fullStr |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_full_unstemmed |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| title_sort |
FMD empty capsids combined with the immunostant particle adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus |
| dc.creator.none.fl_str_mv |
Bidart, Juan Esteban Mignaqui, Ana Clara Kornuta, Claudia Alejandra Lupi, Giuliana Gammella, Mariela Soria, Ivana Galarza, Roxana Ivon Ferella, Alejandra Cardillo, Sabrina Beatriz Langellotti, Cecilia Ana Quattrocchi, Valeria Durocher, Yves Wigdorovitz, Andres Marcipar, Ivan Zamorano, Patricia Ines |
| author |
Bidart, Juan Esteban |
| author_facet |
Bidart, Juan Esteban Mignaqui, Ana Clara Kornuta, Claudia Alejandra Lupi, Giuliana Gammella, Mariela Soria, Ivana Galarza, Roxana Ivon Ferella, Alejandra Cardillo, Sabrina Beatriz Langellotti, Cecilia Ana Quattrocchi, Valeria Durocher, Yves Wigdorovitz, Andres Marcipar, Ivan Zamorano, Patricia Ines |
| author_role |
author |
| author2 |
Mignaqui, Ana Clara Kornuta, Claudia Alejandra Lupi, Giuliana Gammella, Mariela Soria, Ivana Galarza, Roxana Ivon Ferella, Alejandra Cardillo, Sabrina Beatriz Langellotti, Cecilia Ana Quattrocchi, Valeria Durocher, Yves Wigdorovitz, Andres Marcipar, Ivan Zamorano, Patricia Ines |
| author2_role |
author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Foot-and-mouth Disease Aphthovirus Vaccine Adjuvants Immunity Protection Fiebre Aftosa Virus Fiebre Aftosa Coadyuvantes de Vacunas Inmunidad Protección |
| topic |
Foot-and-mouth Disease Aphthovirus Vaccine Adjuvants Immunity Protection Fiebre Aftosa Virus Fiebre Aftosa Coadyuvantes de Vacunas Inmunidad Protección |
| dc.description.none.fl_txt_mv |
Foot and Mouth Disease Virus (FMDV) causes economy losses and is controlled by vaccination in many countries. Vaccine formulations based on empty capsids or Virus-Like Particles (VLPs) have the advantage of avoiding the biological hazard of using infectious FMDV, albeit are poorly immunogenic. Recently, we have described that ISPA a new Immune Stimulating Complex adjuvant, is useful to improve the response against FMD of vaccines that use inactivated virus. Now, the adjuvant effects of ISPA and ISA 206 (water/oil/water) on a VLPs-based FMD vaccine were evaluated. VLPs (strain A/Argentina/2001) were obtained in mammalian cell cultures and their elicitation of an immune response against FMDV with and without ISPA or ISA 206 was evaluated in mice as a first approach. Notably, VLPs-ISPA and VLPs-ISA 206 vaccines induced protection against viral challenge in 100 % of mice, while protection induced by VLPs alone was of 40 %. Total and neutralizing FMDV antibodies were higher in the VLPs-ISPA and VLPs-ISA 206 groups compared to the VLPs group. VLPs-ISPA induced significantly higher (p < 0.001) IgG1, IgG2a, IgG2b and IgG3 titers than the VLPs vaccine. Moreover, in comparison with non-adjuvanted VLPs, VLPs-ISPA and VLPs-ISA 206 elicited an increased virus-specific T response, including higher IFNγ+/CD8 + lymphocyte production in mice. When these vaccines were tested in calves, antibody titers reached an Expected Percentage of Protection (EPP) above 90 % in the case of the VLPs-ISPA and VLPs-ISA 206 vaccines, while, in the VLPs group, EPP reached 25 %. IFNγ levels secreted by mononuclear cells of VLP-ISPA-vaccinated cattle were significantly higher than in the VLPs group. Overall, the results demonstrate that VLPs-ISPA or VLPs-ISA 206 are promising formulations for the development of a novel FMD vaccine. Instituto de Virología Fil: Bidart, Juan Esteban. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Bidart, Juan Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Mignaqui, Ana Clara. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Bariloche. Instituto de Investigaciones Forestales y Agropecuarias Bariloche; Argentina Fil: Mignaqui, Ana Clara. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Kornuta, Claudia Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Kornuta, Claudia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Lupi, Giuliana. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas; Argentina Fil: Lupi, Giuliana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Gammella, Mariela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Gammella, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Soria, Ivana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Soria, Ivana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Galarza, Roxana Ivon. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Galarza, Roxana Ivon. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ferella, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Ferella, Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Cardillo, Sabrina Beatriz. Biogénesis-Bagó; Argentina Fil: Langellotti, Cecilia Ana. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Langellotti, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Quattrocchi, Valeria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Quattrocchi, Valeria. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Durocher, Yves. Human Health Therapeutics Research Center, National Research Council Canada; Canadá Fil: Wigdorovitz, Andres. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Wigdorovitz, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Marcipar, Ivan Sergio. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Tecnología Inmunológica; Argentina Fil: Marcipar, Ivan Sergio. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Zamorano, Patricia Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Zamorano, Patricia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Zamorano, Patricia Ines. Universidad del Salvador; Argentina |
| description |
Foot and Mouth Disease Virus (FMDV) causes economy losses and is controlled by vaccination in many countries. Vaccine formulations based on empty capsids or Virus-Like Particles (VLPs) have the advantage of avoiding the biological hazard of using infectious FMDV, albeit are poorly immunogenic. Recently, we have described that ISPA a new Immune Stimulating Complex adjuvant, is useful to improve the response against FMD of vaccines that use inactivated virus. Now, the adjuvant effects of ISPA and ISA 206 (water/oil/water) on a VLPs-based FMD vaccine were evaluated. VLPs (strain A/Argentina/2001) were obtained in mammalian cell cultures and their elicitation of an immune response against FMDV with and without ISPA or ISA 206 was evaluated in mice as a first approach. Notably, VLPs-ISPA and VLPs-ISA 206 vaccines induced protection against viral challenge in 100 % of mice, while protection induced by VLPs alone was of 40 %. Total and neutralizing FMDV antibodies were higher in the VLPs-ISPA and VLPs-ISA 206 groups compared to the VLPs group. VLPs-ISPA induced significantly higher (p < 0.001) IgG1, IgG2a, IgG2b and IgG3 titers than the VLPs vaccine. Moreover, in comparison with non-adjuvanted VLPs, VLPs-ISPA and VLPs-ISA 206 elicited an increased virus-specific T response, including higher IFNγ+/CD8 + lymphocyte production in mice. When these vaccines were tested in calves, antibody titers reached an Expected Percentage of Protection (EPP) above 90 % in the case of the VLPs-ISPA and VLPs-ISA 206 vaccines, while, in the VLPs group, EPP reached 25 %. IFNγ levels secreted by mononuclear cells of VLP-ISPA-vaccinated cattle were significantly higher than in the VLPs group. Overall, the results demonstrate that VLPs-ISPA or VLPs-ISA 206 are promising formulations for the development of a novel FMD vaccine. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-09-08T12:05:18Z 2021-09-08T12:05:18Z 2021-05 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/20.500.12123/10200 https://www.sciencedirect.com/science/article/abs/pii/S0168170221000460 1872-7492 https://doi.org/10.1016/j.virusres.2021.198339 |
| url |
http://hdl.handle.net/20.500.12123/10200 https://www.sciencedirect.com/science/article/abs/pii/S0168170221000460 https://doi.org/10.1016/j.virusres.2021.198339 |
| identifier_str_mv |
1872-7492 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repograntAgreement/INTA/2019-PD-E5-I105-001/2019-PD-E5-I105-001/AR./Patógenos animales: su interacción con el hospedador y el medio ambiente. Impacto en productividad, ecosistemas, sanidad animal y salud pública en el marco “Una Salud” |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/restrictedAccess |
| eu_rights_str_mv |
restrictedAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
Virus Research 297 : 198339 (Mayo 2021) reponame:INTA Digital (INTA) instname:Instituto Nacional de Tecnología Agropecuaria |
| reponame_str |
INTA Digital (INTA) |
| collection |
INTA Digital (INTA) |
| instname_str |
Instituto Nacional de Tecnología Agropecuaria |
| repository.name.fl_str_mv |
INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria |
| repository.mail.fl_str_mv |
tripaldi.nicolas@inta.gob.ar |
| _version_ |
1846143538664833024 |
| score |
12.712165 |